Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study. [electronic resource]
Producer: 20170612Description: 304-315 p. digitalISSN:- 1432-1459
- Adjuvants, Immunologic -- administration & dosage
- Adult
- Benzazepines -- adverse effects
- Brain -- diagnostic imaging
- Double-Blind Method
- Drug Therapy, Combination -- adverse effects
- Female
- Glatiramer Acetate -- administration & dosage
- Gray Matter -- diagnostic imaging
- Histamine Antagonists -- adverse effects
- Humans
- Injections, Intramuscular
- Interferon beta-1a -- administration & dosage
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Multiple Sclerosis, Relapsing-Remitting -- diagnostic imaging
- Myelin Sheath -- drug effects
- Neuroprotective Agents -- adverse effects
- Single-Blind Method
- White Matter -- diagnostic imaging
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.